Estimated marginal effects of sensitivity analyses in alternate outcome definitions, outpatient only cohort and combined inpatient/outpatient cohorts
| OAT-RX and OAT-laboratories | OAT-laboratories | OAT-outpatients | OAT-all | |||||
|---|---|---|---|---|---|---|---|---|
| 18–40 years | 0.01 | (−0.04 to 0.07) | 0.01 | (−0.03 to 0.06) | −0.02 | (−0.07 to 0.03) | 0.01 | (−0.03 to 0.04) |
| 61–70 years | −0.02 | (−0.04 to 0.01) | −0.18*** | (−0.21 to −0.14) | 0.02 | (−0.01 to 0.06) | 0.01 | (−0.02 to 0.04) |
| 71+ years | −0.12*** | (−0.16 to −0.09) | −0.38*** | (−0.43 to −0.34) | −0.05* | (−0.09 to −0.01) | −0.09*** | (−0.11 to −0.06) |
| Gender (male) | 0.02 | (−0.00 to 0.04) | 0.01 | (−0.01 to 0.03) | 0.06*** | (0.03 to 0.08) | 0.04*** | (0.02 to 0.06) |
| Charlson (0) | 0.02 | (−0.02 to 0.06) | 0.03 | (−0.00 to 0.05) | 0.03 | (−0.01 to 0.07) | 0.01 | (−0.01 to 0.04) |
| Charlson (2) | −0.03 | (−0.06 to 0.01) | −0.02 | (−0.05 to 0.01) | −0.04 | (−0.08 to 0.01) | −0.05** | (−0.08 to −0.01) |
| Charlson (3–4) | −0.00 | (−0.05 to 0.04) | −0.04* | (−0.07 to −0.00) | −0.05 | (−0.09 to 0.00) | −0.05** | (−0.08 to −0.01) |
| Charlson (5+) | −0.12*** | (−0.16 to −0.07) | −0.07*** | (−0.11 to −0.03) | −0.11*** | (−0.17 to −0.05) | −0.13*** | (−0.17 to −0.09) |
| CHADS2 (0–1) | −0.00 | (−0.04 to 0.04) | 0.02 | (−0.01 to 0.05) | 0.02 | (−0.02 to 0.06) | 0.00 | (−0.03 to 0.03) |
| CHADS2( 3–4) | −0.04* | (−0.08 to −0.00) | −0.01 | (−0.03 to 0.02) | −0.01 | (−0.05 to 0.03) | −0.03* | (−0.05 to −0.00) |
| CHADS2 (5+) | −0.02 | (−0.08 to 0.04) | −0.04 | (−0.10 to 0.02) | −0.04 | (−0.10 to 0.03) | −0.04 | (−0.09 to 0.01) |
| Rural | −0.00 | (−0.07 to 0.06) | −0.04* | (−0.08 to −0.01) | −0.05 | (−0.11 to 0.01) | −0.03 | (−0.07 to 0.01) |
| Micropolitan | −0.01 | (−0.06 to 0.04) | −0.03** | (−0.05 to −0.01) | 0.00 | (−0.05 to 0.05) | −0.01 | (−0.04 to 0.02) |
| Postperiod | −0.02 | (−0.05 to 0.01) | 0.03** | (0.01 to 0.05) | 0.01 | (−0.02 to 0.04) | −0.01 | (−0.03 to 0.01) |
| Treatment group | −0.38*** | (−0.42 to −0.34) | −0.14*** | (−0.18 to −0.10) | −0.44*** | (−0.50 to −0.39) | −0.42*** | (−0.46 to −0.38) |
| Post-treatment | 0.09* | (0.02 to 0.16) | 0.03 | (−0.03 to 0.09) | 0.17*** | (0.09 to 0.25) | 0.14*** | (0.08 to 0.19) |
| Negative control | −0.44*** | (−0.53 to −0.36) | −0.21*** | (−0.27 to −0.15) | −0.49*** | (−0.64 to −0.34) | −0.49*** | (−0.57 to −0.40) |
| Post-negative control | −0.03 | (−0.19 to 0.13) | −0.02 | (−0.11 to 0.08) | 0.09 | (−0.10 to 0.29) | 0.02 | (−0.10 to 0.14) |
| 0 prediagnosis visits | −0.05* | (−0.09 to −0.00) | −0.06*** | (−0.10 to −0.03) | 0.09** | (0.03 to 0.14) | 0.02 | (−0.01 to 0.06) |
| 2+ prediagnosis visits | 0.05*** | (0.02 to 0.08) | 0.04*** | (0.02 to 0.07) | 0.08*** | (0.04 to 0.12) | 0.06*** | (0.03 to 0.08) |
| Primary stroke centre | −0.01 | (−0.06 to 0.04) | −0.02 | (−0.05 to 0.00) | ||||
| GWTG participation | −0.01 | (−0.04 to 0.01) | −0.00 | (−0.03 to 0.02) | ||||
| 4–99 beds | −0.04* | (−0.09 to −0.00) | 0.01 | (−0.02 to 0.04) | ||||
| 500+ beds | −0.03 | (−0.07 to 0.01) | −0.01 | (−0.05 to 0.03) | ||||
| 25+ miles | −0.10*** | (−0.15 to −0.05) | −0.04*** | (−0.06 to −0.02) | ||||
| Rural provider | 0.08 | (−0.00 to 0.17) | 0.05 | (−0.01 to 0.10) | 0.12** | (0.04 to 0.20) | 0.11*** | (0.05 to 0.17) |
| Micropolitan provider | 0.05* | (0.00 to 0.09) | 0.04* | (0.00 to 0.08) | 0.01 | (−0.04 to 0.06) | 0.04* | (0.01 to 0.07) |
| Inpt Index Claim | −0.03** | (−0.05 to −0.01) | ||||||
| Observations | 5235 | 5235 | 4694 | 9380 | ||||
95% CIs in parentheses.
*p<0.05.
**p<0.01.
***p<0.001.
CHADS2, C—congestive heart failure, H—hypertension, A—>75 years, D—diabetes mellitus, S—prior stroke or stroke symptoms; GWTG, Get With The Guidelines; Inpt, inpatient; OAT, oral anticoagulation therapy; RX, prescription.